FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138059780> ?p ?o ?g. }

• W2138059780 endingPage "481" @default.
• W2138059780 startingPage "474" @default.
• W2138059780 abstract "Background/Aims This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity. Methods Twenty-seven Child-Pugh A cirrhotics (76% male, 59% HCV) with untreated large/multifocal HCC received chemoembolization with doxorubicin loaded DEBs at doses adjusted for bilirubin and body surface (range: 47–150 mg). Clinical and analytical data were recorded at 24 and 48 h, 7, 14 and 30 days after first and second TACE. Response rate was assessed by CT at 6 months. Blood samples were obtained in 13 patients at 5, 20, 40, 60, 120 min, 6, 24, 48 and 168 h to determine doxorubicin Cmax and AUC. Results DEB-TACE was well tolerated with an acceptable safety profile. Two cases developed liver abscess, one leading to death. Response rate was 75% (66.6% on intention-to-treat). Doxorubicin Cmax and AUC were significantly lower in DEB-TACE patients (78.97 ± 38.3 ng/mL and 662.6 ± 417.6 ng/mL min) than in conventional TACE (2341.5 ± 3951.9 ng/mL and 1812.2 ± 1093.7 ng/mL min, p = 0.00002 and p = 0.001, respectively). After a median follow-up of 27.6 months, 1- and 2-year survival is 92.5% and 88.9%, respectively. Conclusions Chemoembolization using DEBs is an effective procedure with a favorable pharmacokinetic profile. This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity. Twenty-seven Child-Pugh A cirrhotics (76% male, 59% HCV) with untreated large/multifocal HCC received chemoembolization with doxorubicin loaded DEBs at doses adjusted for bilirubin and body surface (range: 47–150 mg). Clinical and analytical data were recorded at 24 and 48 h, 7, 14 and 30 days after first and second TACE. Response rate was assessed by CT at 6 months. Blood samples were obtained in 13 patients at 5, 20, 40, 60, 120 min, 6, 24, 48 and 168 h to determine doxorubicin Cmax and AUC. DEB-TACE was well tolerated with an acceptable safety profile. Two cases developed liver abscess, one leading to death. Response rate was 75% (66.6% on intention-to-treat). Doxorubicin Cmax and AUC were significantly lower in DEB-TACE patients (78.97 ± 38.3 ng/mL and 662.6 ± 417.6 ng/mL min) than in conventional TACE (2341.5 ± 3951.9 ng/mL and 1812.2 ± 1093.7 ng/mL min, p = 0.00002 and p = 0.001, respectively). After a median follow-up of 27.6 months, 1- and 2-year survival is 92.5% and 88.9%, respectively. Chemoembolization using DEBs is an effective procedure with a favorable pharmacokinetic profile." @default.
• W2138059780 created "2016-06-24" @default.
• W2138059780 creator A5009935938 @default.
• W2138059780 creator A5023733918 @default.
• W2138059780 creator A5046826317 @default.
• W2138059780 creator A5052975894 @default.
• W2138059780 creator A5055123026 @default.
• W2138059780 creator A5055692985 @default.
• W2138059780 creator A5057743208 @default.
• W2138059780 creator A5067464504 @default.
• W2138059780 creator A5078639078 @default.
• W2138059780 creator A5080019152 @default.
• W2138059780 creator A5084106169 @default.
• W2138059780 date "2007-03-01" @default.
• W2138059780 modified "2023-10-18" @default.
• W2138059780 title "Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics" @default.
• W2138059780 cites W1975154077 @default.
• W2138059780 cites W1982036382 @default.
• W2138059780 cites W1993150469 @default.
• W2138059780 cites W1997869242 @default.
• W2138059780 cites W2008289958 @default.
• W2138059780 cites W2017352677 @default.
• W2138059780 cites W2020215421 @default.
• W2138059780 cites W2033802014 @default.
• W2138059780 cites W2049806901 @default.
• W2138059780 cites W2050102533 @default.
• W2138059780 cites W2052552898 @default.
• W2138059780 cites W2052627882 @default.
• W2138059780 cites W2054065142 @default.
• W2138059780 cites W2056302939 @default.
• W2138059780 cites W2056476092 @default.
• W2138059780 cites W2078674257 @default.
• W2138059780 cites W2090107622 @default.
• W2138059780 cites W2094488950 @default.
• W2138059780 cites W2103637700 @default.
• W2138059780 cites W2122583281 @default.
• W2138059780 cites W2125763116 @default.
• W2138059780 cites W2139248078 @default.
• W2138059780 cites W2143515276 @default.
• W2138059780 cites W2147172608 @default.
• W2138059780 cites W2158574491 @default.
• W2138059780 cites W2163050497 @default.
• W2138059780 cites W2163486683 @default.
• W2138059780 doi "https://doi.org/10.1016/j.jhep.2006.10.020" @default.
• W2138059780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17239480" @default.
• W2138059780 hasPublicationYear "2007" @default.
• W2138059780 type Work @default.
• W2138059780 sameAs 2138059780 @default.
• W2138059780 citedByCount "849" @default.
• W2138059780 countsByYear W21380597802012 @default.
• W2138059780 countsByYear W21380597802013 @default.
• W2138059780 countsByYear W21380597802014 @default.
• W2138059780 countsByYear W21380597802015 @default.
• W2138059780 countsByYear W21380597802016 @default.
• W2138059780 countsByYear W21380597802017 @default.
• W2138059780 countsByYear W21380597802018 @default.
• W2138059780 countsByYear W21380597802019 @default.
• W2138059780 countsByYear W21380597802020 @default.
• W2138059780 countsByYear W21380597802021 @default.
• W2138059780 countsByYear W21380597802022 @default.
• W2138059780 countsByYear W21380597802023 @default.
• W2138059780 crossrefType "journal-article" @default.
• W2138059780 hasAuthorship W2138059780A5009935938 @default.
• W2138059780 hasAuthorship W2138059780A5023733918 @default.
• W2138059780 hasAuthorship W2138059780A5046826317 @default.
• W2138059780 hasAuthorship W2138059780A5052975894 @default.
• W2138059780 hasAuthorship W2138059780A5055123026 @default.
• W2138059780 hasAuthorship W2138059780A5055692985 @default.
• W2138059780 hasAuthorship W2138059780A5057743208 @default.
• W2138059780 hasAuthorship W2138059780A5067464504 @default.
• W2138059780 hasAuthorship W2138059780A5078639078 @default.
• W2138059780 hasAuthorship W2138059780A5080019152 @default.
• W2138059780 hasAuthorship W2138059780A5084106169 @default.
• W2138059780 hasConcept C112705442 @default.
• W2138059780 hasConcept C126322002 @default.
• W2138059780 hasConcept C126894567 @default.
• W2138059780 hasConcept C141071460 @default.
• W2138059780 hasConcept C22979827 @default.
• W2138059780 hasConcept C2776694085 @default.
• W2138059780 hasConcept C2777035434 @default.
• W2138059780 hasConcept C2778019345 @default.
• W2138059780 hasConcept C2778455285 @default.
• W2138059780 hasConcept C2779690883 @default.
• W2138059780 hasConcept C2781303535 @default.
• W2138059780 hasConcept C71924100 @default.
• W2138059780 hasConcept C90924648 @default.
• W2138059780 hasConcept C98274493 @default.
• W2138059780 hasConceptScore W2138059780C112705442 @default.
• W2138059780 hasConceptScore W2138059780C126322002 @default.
• W2138059780 hasConceptScore W2138059780C126894567 @default.
• W2138059780 hasConceptScore W2138059780C141071460 @default.
• W2138059780 hasConceptScore W2138059780C22979827 @default.
• W2138059780 hasConceptScore W2138059780C2776694085 @default.
• W2138059780 hasConceptScore W2138059780C2777035434 @default.
• W2138059780 hasConceptScore W2138059780C2778019345 @default.
• W2138059780 hasConceptScore W2138059780C2778455285 @default.
• W2138059780 hasConceptScore W2138059780C2779690883 @default.
• W2138059780 hasConceptScore W2138059780C2781303535 @default.

• next